Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : Axon is developing AADvac1 as a vaccine with the potential to halt the progression of tau pathology in Alzheimer's disease. AADvac1 is currently the most clinically-advanced tau immonotherapy in development.
Product Name : AADvac1
Product Type : Vaccine
Upfront Cash : Inapplicable
January 11, 2021
Lead Product(s) : COVID-19 Peptide Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Axon Neuroscience Has a Promising Peptide Vaccine Against COVID-19 in Development
Details : Axon used its established peptide-based vaccine platform to produce a novel prophylactic COVID-19 vaccine, intended to treat infected patients and protect healthy individuals from infection.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
September 04, 2020
Lead Product(s) : COVID-19 Peptide Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Axon Presented Positive Phase II Trial Results of AADvac1 at AAT-AD/PD 2020
Details : A highly significant impact on neurodegeneration was shown on brain proteins in plasma - Neurofilament Light Chain, and CSF - Tau and p-Tau, and Diffusion Tensor Imaging.
Product Name : AADvac1
Product Type : Vaccine
Upfront Cash : Inapplicable
March 04, 2020
Reset All
